Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation

Hsu-Yu Chen, Chun Huang, Lu Tian, Xiao Huang, Chennan Zhang, George N. Llewellyn, Geoffrey L. Rogers, Kevin Andresen, Maurice R. G. O’Gorman, Ya-Wen Chen, @Paula M. Cannon

Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
Hastings Center for Pulmonary Research, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles/Keck School of Medicine of USC, Los Angeles, California, USA

ABSTRACT The high pathogenicity of SARS-CoV-2 requires it to be handled under biosafety level 3 conditions. Consequently, Spike protein-pseudotyped vectors are a useful tool to study viral entry and its inhibition, with retroviral, lentiviral (LV), and vesicular stomatitis virus (VSV) vectors the most commonly used systems. Methods to increase the titer of such vectors commonly include concentration by ultracentrifugation and truncation of the Spike protein cytoplasmic tail. However, limited studies have examined whether such a modification also impacts the protein’s function. Here, we optimized concentration methods for SARS-CoV-2 Spike-pseudotyped VSV vectors, finding that tangential flow filtration produced vectors with more consistent titers than ultracentrifugation. We also examined the impact of Spike tail truncation on transduction of various cell types and sensitivity to convalescent serum neutralization. We found that tail truncation increased Spike incorporation into both LV and VSV vectors and resulted in enhanced titers but had no impact on sensitivity to convalescent serum. In addition, we analyzed the effect of the D614G mutation, which became a dominant SARS-CoV-2 variant early in the pandemic. Our studies revealed that, similar to the tail truncation, D614G independently increases Spike incorporation and vector titers, but this effect is masked by also including the cytoplasmic tail truncation. Therefore, the use of full-length Spike protein, combined with tangential flow filtration, is recommended as a method to generate high titer pseudotyped vectors that retain native Spike protein functions.

IMPORTANCE Pseudotyped viral vectors are useful tools to study the properties of viral fusion proteins, especially those from highly pathogenic viruses. The Spike protein of SARS-CoV-2 has been investigated using pseudotyped lentiviral and VSV vector systems, where truncation of its cytoplasmic tail is commonly used to enhance Spike incorporation into vectors and to increase the titers of the resulting vectors. However, our studies have shown that such effects can also mask the phenotype of the D614G mutation in the ectodomain of the protein, which was a dominant variant arising early in the COVID-19 pandemic. To better ensure the authenticity of Spike protein phenotypes when using pseudotyped vectors, we recommend using full-length Spike proteins, combined with tangential flow filtration methods of concentration if higher-titer vectors are required.

KEYWORDS D614G mutation, SARS-CoV-2, Spike protein, cytoplasmic tail truncation, pseudotyped vectors
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was first reported in Wuhan, China, in December 2019 (1). The disease rapidly spread worldwide, causing over 150 million confirmed cases and more than 3 million reported deaths by May 2021 (2). The accompanying worldwide research effort has resulted in a large number of vaccine candidates and both national and international clinical trials to assess novel and repurposed drug regimens (3). In the United States, the SARS-CoV-2 Spike glycoprotein has been a primary target of such efforts. Spike is a major viral antigen that induces protective immune responses in COVID-19 patients (4–6) and mediates cell entry by binding to angiotensin-converting enzyme 2 (ACE2) (1, 7, 8) or other receptors (9, 10) and employs cellular proteases such as TMPRSS2 to prime the Spike protein for membrane fusion (11, 12). ACE2 is expressed in the human respiratory system (13), especially on type II pneumocytes (14), which are the main target cell for SARS-CoV-2 infection. Expression of ACE2 in other organs also allows infection outside the lung (13).

Due to the high pathogenicity of SARS-CoV-2, biosafety level 3 (BSL3) labs are required for studies that involve replication-competent virus. Therefore, investigators often use Spike protein pseudovirus vector systems, based on replication-incompetent vector particles and attenuated or conditional viruses. Identification of an optimal pseudovirus system for any particular viral entry glycoprotein typically involves comparing the most commonly used systems: replication-incompetent lentiviral (LV) or retroviral (RV) vectors or conditional vesicular stomatitis viruses (VSV) that are deleted for the VSV glycoprotein (G) (15, 16). SARS-CoV-2 Spike protein can pseudotype all three vector systems, which have been used to investigate viral entry (11, 17–19), neutralization by monoclonal antibodies or convalescent plasma (4, 5, 17, 20–28), and entry inhibitors (17, 24, 29, 30) and to characterize surging viral variants (31–45). In approximately one-third of these studies, deletions of 18 to 21 amino acids from the cytoplasmic tail of Spike were used to enhance vector titers and thereby facilitate the study.

Cytoplasmic tail truncation of viral glycoproteins is a common strategy to enhance pseudovirus formation since this can remove sterical interference that may occur between the heterologous viral glycoproteins and the vector matrix or capsid proteins (46–51). Also employed are cytoplasmic tail swaps, whereby the tail from the natural viral glycoprotein is used to create a chimeric glycoprotein with enhanced incorporation properties (47, 52). However, we and others have shown that tail modifications can also have functional consequences, for example, removing endocytosis signals that lead to increased cell surface levels and enhanced incorporation into vector particles (53, 54), alterations of the ectodomain conformation (53, 55), changes to fusogenicity (47, 55–57), and altered antigenic characteristics (58, 59).

SARS-CoV-2 Spike contains a putative endoplasmic reticulum (ER) retention signal (KLHYT) at its C terminus, which is removed by the tail truncations of 13 amino acids (60) or 18 to 21 amino acids that are frequently employed (23, 25, 61–63). Compared to the full-length Spike, such truncations were reported to generate ~10- to 20-fold higher titers of both LV vectors (23, 60, 61, 63) and VSV vectors (25, 61, 62). Truncated Spike also enhances RV vector titers, albeit with a smaller effect compared with LV and VSV vectors (61). Havranek et al. (62) and Yu et al. (60) investigated the mechanism for such an effect for VSV and LV pseudoviruses and found that tail truncation enhanced both Spike incorporation into the viral particles and cell-cell fusion for Spike-expressing cells without altering cell surface expression levels. However, the impact of Spike tail truncations on any other ectodomain functions remains unclear.

In this report, we compared the practicality and functionality of using Spike pseudotyped vectors based on LV and VSV and pseudotyped with either full-length or tail truncated proteins. We compared methods to prepare such vectors and identified tangential flow filtration as a facile method that is superior to ultracentrifugation and allows efficient production at a larger scale. An optimized system based on VSV vectors was used to assess the impact of the Spike mutation D614G (35) and to assess neutralizing activity in convalescent serum. Our studies determined that although Spike tail
truncation boosts incorporation into vectors and enhances the titers achieved for unconcentrated supernatants, it also blunted the ability to observe differences caused by this specific Spike mutation. We therefore recommend that studies using Spike pseudotyped vectors retain the natural full-length cytoplasmic tail and use other strategies, such as concentration method and vector system choice, to achieve the required vector titers.

RESULTS

Spike cytoplasmic tail truncation facilitates vector incorporation and enhances titer. Cytoplasmic tail truncation of SARS-CoV-2 Spike has been reported to enhance the transduction efficiency of pseudotyped LV and VSV vectors (23, 60, 61, 63), with the effect suggested to be the result of enhanced incorporation and/or fusogenicity of Spike (60, 62). Using both the full-length Spike (S) and an 18-amino-acid cytoplasmic tail truncation (SΔ18), we generated pseudotyped LV and VSV vectors carrying reporter green fluorescent protein (GFP) or luciferase genes, respectively. We compared the ability of the two Spike proteins to be incorporated into the vectors and to transduce HeLa cells expressing human ACE2 (HeLa-ACE2). Transduction by LV-GFP vectors was analyzed at 48 h posttransduction, while VSV-Luc vectors were analyzed as early as 16 to 24 h posttransduction.

Consistent with previous findings, we found that the cytoplasmic tail truncation increased vector transduction efficiency on HeLa-ACE2 cells by approximately 4- and 30-fold for the LV-GFP and VSV-Luc vectors, respectively (Fig. 1A). We also observed a significant increase in incorporation for the truncated Spike protein in both vector systems (Fig. 1B) while having no impact on other viral particle proteins (Fig. 1B) or vector genome copy number (Fig. 1C). Together, these results suggest that cytoplasmic tail truncation increases Spike incorporation into both LV and VSV particles, and this results in higher infectivity per particle. Since the VSV-Luc vectors have a faster readout time, we chose this pseudovirus system for the rest of our studies.

Susceptibility of different cell lines and lung organoids to Spike protein pseudovectors. Next, we tested the permissivity of different cell lines and a lung organoid model to SΔ18 pseudotyped VSV vectors. In agreement with previous findings, several ACE2-expressing cells were found to be susceptible to the vectors (1, 11), while ACE2 overexpression was required to support transduction of HeLa cells (Fig. 2A). We also evaluated an alternative transduction protocol with a shortened timeline, whereby trypsinized HeLa and HeLa-ACE2 cells were incubated with vectors simultaneously with seeding onto plates instead of transduction occurring 24 h after seeding (64). However, this protocol significantly reduced the transduction efficiency (Fig. 2B), which we hypothesize is a result of reduced cell surface ACE2 after trypsinization (Fig. 2C).

Finally, we tested the susceptibility of a three-dimensional lung bud organoid model to SΔ18 VSV pseudovectors carrying a GFP reporter. Compared to cell lines,
lung organoids provide more physiologically relevant models of virus infection and have been used to identify candidate COVID-19 therapeutics (30). S\textsubscript{D18}-pseudotyped VSV-GFP vectors were able to efficiently transduce the cells, with GFP expression observed throughout the organoid by 24 h (Fig. 2D).

**FIG 2** Transduction of cells by Spike VSV pseudovectors. (A) Indicated cell lines were transduced with equal amounts of S\textsubscript{D18} VSV-Luc vectors and luciferase activity in cell lysates analyzed 24 h later. Shown are means and standard deviations from 3 independent vector stocks. (B) HeLa and HeLa-ACE2 cells were detached from culture flasks by trypsin, seeded into 96-well plates, and transduced (Td) with equal amounts of S\textsubscript{D18} VSV-Luc vectors, either immediately (0 h) or 24 h after seeding, and luciferase was measured 24 h later. Data from 9 different wells in a single experiment are shown. ****, \(P < 0.001\), multiple t test. (C) ACE2 expression levels on cell surface measured by flow cytometry. Cells were stained with anti-ACE2 antibody at 0 or 6 h after trypsinization. Mean and standard deviation MFI from four (HeLa) or five (HeLa-ACE2) independent experiments are shown. (D) Lung bud organoids were transduced with equal amounts of VSV-GFP vectors pseudotyped with S\textsubscript{D18} or control (bald) vectors with no Spike protein. GFP expression was visualized 24 h later. Scale bars represent 100 \(\mu\text{m}\).

TFF facilitates scale-up of vector production and concentration. To identify an optimal method for concentration of Spike protein pseudovectors suitable for a research laboratory, we compared ultracentrifugation through a 20\% (wt/vol) sucrose cushion with tangential flow filtration (TFF). Ultracentrifugation is limited by the capacity of a rotor, for example, SW28 rotors have a maximum capacity of \(\sim 230\) ml of vector supernatant per 2-h run. In contrast, TFF can process much larger volume (65, 66), and a single TFF filter with 1,000-cm\(^2\) surface area can process up to 3,000 ml in 2 h. Larger filter systems with capacities of up to 15 liters are also available. In addition, VSV-G-pseudotyped LV vectors produced by TFF are reported to have a higher recovery rate than when prepared by ultracentrifugation (66).

To compare these approaches, 100 ml of S\textsubscript{D18}-pseudotyped VSV-Luc vector supernatants was subjected to either ultracentrifugation (Ultra) or TFF and concentrated into an 8-ml final stock (12\(\times\), vol/vol). Vector genome copies in the unconcentrated and 12\(\times\) concentrated vector stocks were measured by droplet digital PCR (ddPCR), which revealed slightly better recovery rates following TFF (\(\sim 70\%\)) compared to
ultracentrifugation (~60%) (Fig. 3A and B). At the same time, the transduction efficiencies of the three vector stocks were measured on HeLa-ACE2 cells, using serially diluted vectors (1:5 to 1:450 dilutions) (Fig. 3C). At the higher dilution points, both 12x Ultra and 12x TFF vector preparations produced about a 10-fold higher luciferase signal than the unconcentrated vectors. Interestingly, at the lower dilutions (1:5 and 1:15), the 12x Ultra vector stock showed no enhancement over unconcentrated vectors, while the 12x TFF vector stocks retained their 10-fold higher transduction rates. This observation is suggestive of the presence of an inhibitory factor that is concentrated during ultracentrifugation but was not retained following TFF.

In summary, we found that TFF facilitates large-scale processing of vector stocks, with genomic copy number recovery rates similar to those of the more typical ultracentrifugation method. More importantly, TFF results in vector stocks that retain a more consistent titer throughout a broader range of different dilutions than those produced by ultracentrifugation.

**Cytoplasmic tail truncation alters Spike protein functional properties.** We used the VSV pseudovirus system to examine the impact of the D614G mutation of Spike protein. This mutation was first detected in China and Germany in late January and became the dominant circulating variant of SARS-CoV-2 globally by April 2020 (35). It has functional consequences for the virus, resulting in higher viral loads in the upper respiratory tract of patients (35, 67). In parallel, in vitro studies have shown that D614G enhances replication of the virus on human lung epithelial cells and primary airway tissue (42) and increases replication or transmissibility in human ACE2 transgenic mice and hamster models (42, 68, 69). Effects were also observed using Spike protein pseudoviruses, where the D614G mutation increased Spike incorporation into vector particles, despite minimal or no effect on Spike expression in vector-producing cells (44, 70), and increased transduction rates on various cell lines (31, 33, 35, 38, 44, 63, 71). Of interest, residue 164 is not located within the receptor binding domain (RBD) of Spike, and it has been suggested instead that it impacts Spike protein structure and stability, leading to downstream effects on cell entry (35, 70, 72).

Since we had noted that cytoplasmic tail truncation of Spike protein had effects similar to those of the D614G mutation and increased incorporation rates and transduction efficiencies (Fig. 1), we next examined the impact of the D614G mutation in the context of both full-length and truncated Spike proteins. For the full-length Spike protein, we observed up to 18-fold higher transduction rates for the G614 variant on HeLa-ACE2 cells, with less striking effects on the other cell lines we tested. In contrast,
Transduction rates for the variants in the SΔ18 backbone showed minimal to no differences across the range of cell types tested (Fig. 4A and B). The discrepancy between the behavior of the full-length S and SΔ18 vectors occurred despite similar genome copy numbers (Fig. 4C), ruling out an effect on vector production. We also observed minimal effects on cell surface expression levels of Spike when comparing the different variants in vector-producing cells (Fig. 4D). Instead, in agreement with previous studies using full-length Spike-pseudotyped RV and LV vectors, we found that the D614G mutation enhanced Spike incorporation, albeit with a much larger effect for the full-length Spike versus the truncated protein (9-fold versus 2-fold effect) (Fig. 4E and F).

To further investigate the observation that the magnitude of titer enhancement caused by the G614 mutation in full-length Spike protein varied between different cell types, we also measured the levels of the cellular receptor ACE2 and the protease TMPRSS2 (Fig. 5). This revealed that the largest impact of the mutation occurred in the cells with the highest levels of ACE2, namely, HeLa-ACE2 and, to a lesser extent, Calu-3 cells. We hypothesize that higher ACE2 expression renders such cells more susceptible to transduction by the G614 variants.
to vectors with higher Spike densities due to enhanced avidity between the Spike protein and receptors. In sum, these observations suggest that a primary effect of both the tail truncation and the D614G mutation is on Spike protein incorporation, which in turn leads to enhanced titers, at least on cells with high enough levels of ACE2. Furthermore, it is likely that an upper limit for these effects reduces the impact of the D614G mutation when combined with a tail truncation.

**D614G mutation or cytoplasmic tail truncation does not alter Spike protein sensitivity to convalescent serum.** Spike protein pseudovectors are a useful tool to measure antibody neutralizing activity in COVID-19 patient or convalescent sera (4, 5, 17, 20, 21, 23–25, 27, 28). We examined whether the D614G mutation or the cytoplasmic tail truncation altered sensitivity to neutralization by a panel of convalescent sera. VSV-Luc vectors displaying the four different Spike proteins were incubated with serially diluted sera for 30 min before being applied to HeLa-ACE2 cells. After normalizing values to the luciferase signals obtained from cells transduced in the absence of sera, we observed that all four Spike proteins exhibited similar sensitivities to each serum (Fig. 6). This suggests that neither the D614G mutation nor the cytoplasmic tail truncation alters the sensitivity of the Spike protein to neutralization.

**DISCUSSION**

Pseudotyped vectors are a useful system to study the entry glycoproteins from highly pathogenic viruses such as SARS-CoV-2, as they remove the need for BSL3 laboratory conditions. We confirmed that the SARS-CoV-2 Spike protein was able to pseudotype both LV and VSV vectors and determined that the combination of using a conditional VSV vector and a luciferase reporter gene had the advantage of allowing titers to be read at 16 h posttransduction. Such Spike-pseudotyped VSV vectors supported entry into a variety of mammalian cell types, including lung organoid systems, making them a useful system with which to study SARS-CoV-2 entry under standard laboratory conditions.

Optimization of pseudotyped vectors includes selection of an appropriate concentration method, such as centrifugation, polyethylene glycol (PEG) precipitation, or ultrafiltration. For VSV pseudovectors, we found that concentration by TFF produced vector stocks with higher recovery rates and more consistent titers throughout a dilution series than those produced by ultracentrifugation. TFF also has the advantage of providing a partial purification due to the selective loss of potential contaminants below the cutoff value of the filter and provides a larger processing capacity than ultracentrifugation. As a result, TFF is frequently used to facilitate large-scale vector...
production, including for clinical use (65, 66, 73). In our own experience, 3 liters of supernatant can be concentrated down to 50 ml in 2 h.

Since pseudovector titers can be impacted by incompatibilities between a viral fusion protein and the heterologous viral particle (46–51), an additional strategy to enhance vector titers has been to truncate the fusion protein’s cytoplasmic tail. We found that this approach increased the titers of Spike protein pseudovectors based on both LV and VSV, in agreement with previous reports (23, 25, 60–63). Furthermore, as others have also noted (60, 62), the enhanced vector titers correlated with increased levels of Spike protein incorporation that were not simply the result of higher levels of cell surface expression following tail truncation, and tail truncation has also been reported to enhance the fusogenicity of Spike (60, 62). Together, this suggests that truncation of the cytoplasmic tail could also alter the conformation or function of the protein’s ectodomain, as has been reported for viral fusion proteins in HIV (58), measles virus (57), simian immunodeficiency virus (56), and gibbon ape leukemia virus (47), where truncation of the cytoplasmic tail impacted ectodomain conformation or functions such as receptor binding or fusogenicity.

Our comparison of techniques to enhance vector titers also identified an area for caution. Although cytoplasmic tail truncation enhanced pseudovector titers, they can also have unintended functional consequences. Specifically, we found that the impact of the D614G mutation on Spike protein incorporation and vector titer was obscured by the cytoplasmic tail truncation. A similar lack of effect of the D614G mutation on titer was also reported in another study using a 21-amino-acid deletion of the Spike protein cytoplasmic tail in VSV pseudovectors (62). These findings suggest that tail-truncated Spike proteins should be used with caution for studies analyzing the impact of Spike mutations or to test potential therapeutics targeting SARS-CoV-2 entry.

The mechanism for enhanced incorporation and/or titer by D614G is not entirely understood, but structural analyses have suggested that it could impact Spike protein structure and stability, both within and between Spike monomers. For example, it has been suggested that a glycine at this location could strengthen the association between the S1/S2 subunits through an impact on the epistructure that decreases the intramolecular wrapping in the S1 subunit but promotes intermolecular wrapping between S1 and S2 (72). In an alternative model, the D614G mutation could alter the structure and/or stability of the Spike trimer by abrogating the hydrogen bond...
connecting D614 in the S1 subunit of one monomer with T859 in the S2 subunit of a neighboring monomer (35). These alterations were hypothesized to result in a greater tendency of the G614 monomers to form stable trimers, which, in turn, could facilitate their incorporation into virions. As evidence, a mixture of equal amounts of D614 and G614 Spike variants expressed in vector-producing cells resulted in a higher level of G614 proteins in the incorporated Spike trimers (70).

Finally, we also used the VSV pseudovectors to evaluate the impact of the D614G mutation on infectivity of different cell types and sensitivity to antibody neutralization. Consistent with previous findings using pseudoviruses (33–35, 38, 44, 45) or SARS-CoV-2 virions (42, 68), we found that the G614 variant exhibited enhanced transduction of various cell lines compared to the D614 variant, and that this correlated with increased Spike incorporation into the VSV particles (44, 70). Interestingly, the enhanced transduction effect was more profound in cells with higher ACE2 levels, which may reflect increased avidity between the receptor (ACE2) and the ligand (Spike). Finally, as previously noted, these effects were significantly abrogated when tail truncated variants were used, consistent with an upper limit for the enhancement of Spike incorporation and transduction.

In contrast, the serum neutralization studies revealed no differences in sensitivity for either residue at position 614 and in either of the cytoplasmic tail configurations. This is in agreement with the majority of reports testing the impact of the D614G mutation with full-length Spike pseudovectors or SARS-CoV-2 virus against human convalescent serum (31, 35, 44, 68), serum from convalescent animals (42), or vaccinated humans or animals (45, 68, 74).

In summary, we found that although cytoplasmic tail truncations enhance SARS-CoV-2 Spike protein incorporation into both LV and VSV vectors and enhance the titers of unconcentrated vectors, they can also mask the phenotype of the D614G mutation. Pseudotyped vectors are increasingly being used to study newly emerging SARS-CoV-2 variants, where both full-length (43, 75) and truncated Spike proteins (26, 36, 40) have been used in studies investigating the impact of mutations on Spike protein properties such as ACE2 binding, transduction efficiency, or sensitivity to neutralization. To better ensure the authenticity of the Spike protein functions being investigated in such vectors, we recommend using a full-length Spike protein and combining vector production with TFF if higher titer vectors are required.

MATERIALS AND METHODS

**Plasmids.** Full-length (S) and 18-amino-acid cytoplasmic tail truncated (SΔ18) Spike proteins for the Wuhan-Hu-1 isolate of SARS-CoV-2 (GenBank accession no. MN908947.3) were provided by James Voss (The Scripps Research Institute) in a plasmid pcDNA3.3 backbone. D614G mutants were generated by site-directed mutagenesis. A VSV-G protein expression plasmid was obtained from Addgene (8454; Watertown, MA).

**Cell lines.** 293T, HeLa, HeLa-ACE2, Vero, VeroE6, and Huh7.5 cells were maintained in Dulbecco’s modified Eagle medium (DMEM), and Calu-3 cells were maintained in Eagle’s minimum essential medium (EMEM). All media were supplemented with 4 mM glutamine and 10% fetal bovine serum (FBS). HeLa-ACE2 cells were provided by James Voss and were generated by transduction of HeLa cells with a lentiviral vector packaging a CMV-ACE2 expression cassette. The Huh7.5 cell line was provided by Jae Jung (Cleveland Clinic). All other cell lines were obtained from the ATCC.

**VSV vector production, concentration, and transduction.** Replication-deficient VSVΔG vectors (76), containing expression cassettes for firefly luciferase or GFP in place of the VSV-G protein, were provided by Jae Jung and Oscar Negrete (Sandia National Laboratories), respectively. To generate Spike-pseudotyped VSV vectors, 4 × 10^6 293T cells were seeded in DMEM plus 10% FBS in a 10-cm plate and transfected with 15 μg of Spike expression plasmid 24 h later, using the calcium-phosphate transfection method (76). Medium was replaced 16 h later with 10 ml fresh medium, and after a further 8 h, 5 ml was removed and 2 × 10^6 vector genomes of VSVΔG particles were added for 1 h at 37°C. Following this incubation, cells were washed three times with phosphate-buffered saline (PBS) and incubated for a further 24 h before harvesting supernatants.

For larger-scale production, quantities were adjusted to seed 3 × 10^7 cells in 500-cc^2 plates, transfection with 124.3 μg of Spike expression plasmid, and infection by 1.7 × 10^6 vector genomes of VSVΔG particles per 500-cc^2 plate. To propagate VSVΔG particles, the same protocol was followed but replacing the Spike expression plasmid with the same quantity of a VSV-G expression plasmid, and no PBS washes were performed after infection by VSVΔG.

Vector supernatants were harvested and filtered through 0.45-μm syringe filters and either aliquoted
or concentrated by ultracentrifugation using 20% (wt/vol) sucrose cushions for 2 h at 25,000 rpm in an SW41 or SW28 rotor (Beckman, Indianapolis, IN). Alternatively, scale supernatant preparations were concentrated by tangential flow filtration (TFF) using a polyethersulfone membrane hollow fiber unit with 100-kDa-molecular-weight cutoff and 115-cm² filtration surface (Spectrum Laboratories, Rancho Dominguez, CA) and a KR2i peristaltic pump (Spectrum Laboratories). To perform buffer exchange and prevent filter blockage, every 100 ml of vector supernatant was followed by 100 ml PBS. A 10- to 12-fold concentration from the original volume to an approximately 8-ml final volume was achieved. All vectors were stored at −80°C in aliquots.

**VSV-luciferase vector transductions were performed on tissue culture-treated, 96-well half-area white plates (Corning, Corning, NY), seeded with various cell lines to achieve 50% to 75% confluence at the time of transduction. Vectors were serially diluted and added to the culture to achieve final dilutions of 1:5, 1:15, 1:45, 1:135, and 1:405 and incubated at 37°C for 16 to 24 h. Transduction efficiency was quantified by measuring luciferase activity in cell lysates using Britelite plus (Perkin Elmer, Richmond, California) and following the manufacturer’s protocol. To calculate the fold change in transduction efficiency between D614 and G614 mutants, data from the 1:45 dilution points were used.

To titer VSV-GFP vectors, HeLa-ACE2 cells were seeded at 1 × 10⁴ cells per well in 96-well plates, and the following day, 50 μl of serially diluted unconcentrated vector stocks was added. The final dilutions in the cultures were 1:2, 1:6, 1:18, and 1:27. Transduction efficiency was determined by GFP expression 16 to 24 h after transduction using flow cytometry (Guava easyCye; MilliporeSigma, Burlington, MA) and transducing units (TU) per milliliter calculated from the dilutions showing a linear relationship between the dilution factor and the number of GFP-positive cells.

**Lentiviral vector production, concentration, and transduction.** Lentiviral vectors were generated by transfection of 10-cm plates of 293T cells at 75% confluence, 10 μg of packaging plasmid pCMVdeltaR8.2 (12263; Addgene), and 10 μg of a GFP-expressing vector genome plasmid FUGW (14883; Addgene). Medium was removed 16 h later and replaced with 10 ml fresh DMEM plus 10% FBS. Supernatants were harvested 48 h after transfection, filtered through 0.45-μm syringe filters, and either aliquoted or concentrated by ultracentrifugation using 20% (wt/vol) sucrose cushions for 2 h at 25,000 rpm in an SW41 rotor (Beckman).

HeLa-ACE2 cells were transduced with Spike pseudotyped LV by seeding 1 × 10⁴ cells per well in 96-well plates and adding 50 μl of unconcentrated vector stocks the next day. Transduction efficiency was determined by GFP expression 48 h after transduction using flow cytometry, as described above, and reported as TU per milliliter.

**LV and VSV vector genome titration.** RNA from 160 μl of LV or VSV vector stocks was extracted using a viral RNA minikit (Qiagen, Hilden, Germany) and reverse transcribed into cDNA using SuperScript (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Genome copy number was determined by ddPCR for the WPRE sequences in the LV genome or for phosphoprotein (P) sequences in the VSV genome using the QX200 droplet digital PCR system (Bio-Rad, Hercules, CA) and primer/probe set WPRE-forward (CCTTTCCGGGACTTTCGCTTT), WPRE-reverse (GGCGGCGGTCACGAA), WPRE-probe (6-carboxytetramethylrhodamine [FAM]-ACTCATCGCCGCCTGCCTTGCC-6-carboxytetramethylrhodamine [TAMRA]), P-forward (GTCTTCAGCCTCTACCATATC), P-reverse (AGCAGATTGCCCTTCTTATG), and P-probe (FAM-TGGAGGTACGGAGAATGTCT-IOWA BLACK). Briefly, 6.25 μl of 1:10- and 1:100-diluted cDNA was mixed with forward and reverse primers (final concentration, 900 nM), probe (final concentration, 250 nM), and 2× ddPCR supermix (Bio-Rad) and made up to 25 μl with water. Twenty microliters of each reaction mix was converted to droplets by the QX200 droplet generator, and droplet-partitioned samples were transferred to a 96-well plate and sealed. Thermal cycling was performed with the following conditions: 95°C for 10 min, 40 cycles of 94°C for 30 s, 60°C for 1 min, and 98°C for 10 min. Plates were read on a QX200 reader (Bio-Rad) and DNA copies quantified by detection of FAM-positive droplets.

**Lung bud organoid differentiation and transduction.** Lung bud organoids were generated from human pluripotent stem cells (hPSCs) and validated as previously described (7). hPSC differentiation into endoderm was performed in serum-free differentiation (SFD) medium of Isovie’s modified Dulbecco’s medium–Ham’s F-12 (3:1) (Life Technologies, Carlsbad, CA) supplemented with the following: 1 × N2 (Life Technologies), 0.5× B27 (Life Technologies), 50 μg/ml ascorbic acid, 1 × GlutaMAX (Gibco), 0.4 μM L-methionine, 0.05% bovine serum albumin (BSA), 10 μM Y27632, 0.5 μg/ml human BMP4 (R&D Systems), 2.5 mg/ml human FGF2 (R&D Systems, Minneapolis, MN), and 100 ng/ml human Activin (R&D Systems) in a 5% CO₂, 5% O₂, atmosphere at 37°C for 72 to 76 h. On day 4, endoderm yield was determined by the expression of CXCR4 and c-KIT by flow cytometry. Cells used in all experiments had >9% endoderm yield. For induction of anterior foregut endoderm, embryonic bodies were dissociated into single cells using 0.05% trypsin–0.02% EDTA and plated onto fibronectin-coated, 6-well tissue culture plates (80,000 to 105,000 cells/cm²). Cells were incubated in SFD medium supplemented with 100 ng/ml human Noggin (R&D Systems) and 10 μM SB431542 for 24 h, followed by switching to SFD medium supplemented with 10 μM SB431542 and 1 μM IWP2 (R&D Systems) for another 24 h. At the end of anterior foregut endoderm induction, cells were maintained in SFD medium supplemented with 3 μM CHIR99021 (Cayman), 10 ng/ml human FGF1, 10 ng/ml human KGF, 10 ng/ml human BMP4, and 50 nM all-trans retinoic acid for 48 h when three-dimensional cell clumps formed. Clumps were suspended by gently pipetting around the wells to form lung bud organoids, which were maintained in ultra-low-attachment multiple-well plates (Corning), fed every other day, and used for vector transduction after day 35.

To transduce lung bud organoids, 10 to 20 organoids were picked manually and transferred to 96-well plates, and 10 μl of serially diluted unconcentrated vector stocks was added. The final dilutions in the cultures were 1:2, 1:6, 1:18, and 1:27. Transduction efficiency was determined by GFP expression 16 to 24 h after transduction using flow cytometry (Guava easyCye; MilliporeSigma, Burlington, MA) and transducing units (TU) per milliliter calculated from the dilutions showing a linear relationship between the dilution factor and the number of GFP-positive cells.
well U-bottom plates and transduced with 50 µl of GFP-expressing VSV vectors (1.7 × 10^4 TU/ml). Transduction efficiency was examined by GFP expression 24 h later by fluorescence microscopy.

**Western blot analysis of Spike protein incorporation.** Vector supernatants were concentrated by ultracentrifugation (100-fold), electrophoresed on 4 to 12% Bis-Tris protein gels (Bio-Rad), and transferred to polyvinylidene difluoride membranes using a Trans-Blot turbo transfer system (Bio-Rad). Membranes were blocked with 5% milk in PBST buffer (PBS plus 0.1% Tween 20). The S1 subunit of Spike was detected using SARS-CoV-2 (COVID-19) Spike S1 antibody at 1:1,000 (9083; Prosci); the S2 subunit was detected using anti-SARS-CoV/SARS-CoV-2 (COVID-19) spike antibody clone [1A9] at 1:1,000 (GTX632604; GeneTex); and HIV-1 p24 was detected using anti-BSV M antibody clone U3H12) (EB0011; KeraFest, Boston, MA) at 1:1,000. Horseradish peroxidase (HRP)-conjugated goat anti-mouse and goat anti-rabbit antibodies were used as secondary antibodies (Santa Cruz Biotechnology, Dallas, TX). Blots were imaged by Amersham ECL Prime Western blotting detection reagent (GE Healthcare, Chicago, IL) and Chemidoc (Bio-Rad). Densitometry was measured using ImageJ software (http://rsb.info.nih.gov/ij/).

**ACE2 and TMPRRSS2 cell surface expression by flow cytometry.** Cells were detached from culture flasks by 0.05% trypsin (Corning) and washed once with PBS. One million cells were resuspended in 100 µl PBS and either immediately incubated with anti-ACE2 antibody (AF933; 1:100 dilution; R&D Systems) or anti-TMPRSS2 (H4) antibody (sc-515727 PE; 1:50 dilution; Santa Cruz) or first incubated at 37°C for 6 h with shaking to allow recovery of cell surface proteins after trypsinization. Alexa Fluor 647-conjugated donkey anti-goat antibody (A21447; 1:200 dilution; Thermo Fisher Scientific, Waltham, MA) was used as a secondary antibody, and ACE2 expression was determined by flow cytometry (Guava easyCyte).

**Spike protein cell surface expression.** VSV pseudovector-producing 293T cells were harvested to examine cell surface expression of the Spike protein. The S1 subunit was detected using SARS-CoV-2 (COVID-19) Spike S1 antibody at 1:100 (9083; Prosci, Fort Collins, Colorado), and the S2 subunit was detected using anti-SARS-CoV/SARS-CoV-2 (COVID-19) spike antibody clone [1A9] at 1:100 (GTX632604; GeneTex, Irvine, CA). Allophycocyanin-conjugated goat anti-mouse and donkey anti-rabbit antibodies were used as secondary antibodies (1:100 dilution; Invitrogen), and expression was detected by flow cytometry (Guava easyCyte). The expression levels of different Spike proteins were reported as mean fluorescence intensity (MFI).

**Convalescent serum neutralization.** Convalescent serum from COVID-19 patients or healthy donors (collected before 30 April 2020) was obtained from Children’s Hospital Los Angeles. Convalescent sera were confirmed to be positive for IgG class antibodies against SARS-CoV-2 Spike using anti-SARS-CoV-2 ELISA (IgG) (Euroimmun, Lübeck, Germany) (78).

A suitable dose of Spike-pseudotyped VSV-Luc vectors was used in the neutralization assays to produce approximately 10^7 relative light units (RLU) of luciferase activity on HeLa-ACE2 cells in the absence of serum. A total of 5 × 10^4 HeLa-ACE2 cells were seeded in tissue culture-treated, 96-well half-area white plates (Corning) to achieve 50% to 75% confluence the following day. Convalescent or control sera were 3-fold serially diluted from 1:10 to 1:7,290, and 50 µl was incubated with the predetermined dose of the VSV-Luc vectors for 30 min at 37°C before addition of the mixture to HeLa-ACE2 cells. Cells were incubated at 37°C overnight for 16 to 24 h. Vector transduction efficiency was quantified by measuring luciferase activity as described above and neutralization (%) calculated by normalization to the values obtained on cells transduced without serum.

**ACKNOWLEDGMENTS**

This work was supported by a grant to P.M.C. from the W. M. Keck Foundation COVID-19 Research Fund to the Keck School of Medicine of USC.

We acknowledge the generosity of James Voss, Jae Jung, and Oscar Negrete, who provided COVID-19 reagents, cell lines, and VSVΔG particles.

**REFERENCES**

1. Zhou P, Yang X, Lou Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang R, Di Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273. https://doi.org/10.1038/s41586-020-2012-7.

2. Johns Hopkins University. 2021. Coronavirus Resource Center. Johns Hopkins Coronavirus Resource Center, Baltimore, MD.

3. Umakanthan S, Chattu VR, Ranade AV, Das D, Basavarajegowda A, Bukelo M. 2021. A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19. AMPS Public Health Bulletin 8:137–153. https://doi.org/10.5933/publichealth.2021011.

4. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan A, Finkin S, Häggdöf T, Oliveira TV, Viant C, Hurley A, Hoffmann HH, Milardi KG, Kost RG, Cipolla M, Gordon K, Blanchini F, Chen ST, Ramos V, Patel R, Dizon J, Shimelovich I, Mendoza P, Hartweger H, Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y, Michalidis E, Ashbrook AW, Waltari E, Pak JE, Huey-Tubman KE, Koranda N, Hoffman PR, West AP, Rice CM, Hatzioannou T, Bjorkman PJ, Bieniasz PD, Caskey M, Nussenzweig MC. 2020. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584:437–442. https://doi.org/10.1038/s41586-020-2456-9.

5. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L. 2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584:115–119. https://doi.org/10.1038/s41586-020-2380-z.

6. Mohamed Khoreshahi L, Rokni M, Mokhtari T, Noorbakhsh F. 2021. Immunomodulation, immunopathogenesis and immunotherapeutics of COVID-19: an overview. Int Immunopharmacol 93:107364. https://doi.org/10.1016/j.intimp.2020.107364.
47. Christodouloupoulos I, Cannon PM. 2001. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. J Virol 75:4129–4138. https://doi.org/10.1128/JVI.75.11.4129-4138.2001.

48. Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ. 2017. Targeted cell entry of lentiviral vectors. Mol Ther 16:1427–1436. https://doi.org/10.1038/mt.2017.128.

49. Bender RR, Muth A, Schneider IC, Friedel T, Hartmann J, Plüthken A, Maisner A, Buchholz CJ. 2016. Receptor-targeted Nipah virus glycoproteins improve cell-type selective gene delivery and reveal a preference for membrane-proximal cell attachment. PLoS Pathog 12:e1005641. https://doi.org/10.1371/journal.ppat.1005641.

50. Witting SR, Vailanda P, Gammal AL. 2013. Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction. Gene Ther 20:997–1005. https://doi.org/10.1038/gt.2013.23.

51. Höhne M, Thaler S, Dudda JC, Groner B, Schnierle BS. 1999. Truncation of the human immunodeficiency virus-type-2 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus retroviral vector particles. Virology 261:70–78. https://doi.org/10.1006/viro.1999.9847.

52. Moore MJ, Dorfman T, Li W, Wong SK, Li Y, Kuhn JH, Codere J, Vasiliou N, Han Z, Greenough TC, Farzan M, Choe H. 2004. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol 78:10628–10635. https://doi.org/10.1128/JVI.78.21.10628-10635.2004.

53. Agohil CA, Anderson WF, Cannon PM. 2003. Cytoplasmic tail of moloney murine leukemia virus envelope protein increases envelope protein incorporation into particles and fusogenicity and infectivity. J Virol 77:1281–1291. https://doi.org/10.1128/JVI.77.2.1281-1291.2003.

54. Khetawat D, Broder CC. 2010. A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system. Virol J 7:312–314. https://doi.org/10.1186/1743-422X-7-312.

55. Agohil CA, Matreyek KA, Choi DY, Filone CM, Young S, Lee B. 2007. Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion and destabilizes the fusion intermediate. J Virol 81:4520–4532. https://doi.org/10.1128/JVI.02205-06.

56. Ziegler K, Littman DR. 1993. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity. J Virol 67:2824–2831. https://doi.org/10.1128/JVI.67.7.2824-2831.1993.

57. Cathomen T, Nain Hy, Cattaneo R. 1998. Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol 72:1224–1234. https://doi.org/10.1128/JVI.72.2.1224-1234.1998.

58. Chen J, Kovacs JM, Peng H, Rits-Volloch S, Lu J, Park D, Zablotsky E, Seaman MS, Chen B. 2015. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science 349:191–195. https://doi.org/10.1126/science.aaa9804.

59. White E, Wu F, Chertova E, Bess J, Roser JD, Lifson JD, Hirsch VM. 2017. Truncating the gp41 cytoplasmic tail of simian immunodeficiency virus decreases sensitivity to neutralizing antibodies without increasing the envelope content of virions. J Virol 92:e01687-17. https://doi.org/10.1128/JVI.01687-17.

60. Yu J, Li Z, He X, Gebre MS, Bondzie EA, Wan H, Jacob-Dolan C, Martinez DR, Nikolpa JA, Baric RS, Barouch DH. 2021. Deletion of the SARS-CoV-2 Spike cytoplasmic tail increases infectivity in pseudovirus neutralization assays. J Virol 95:e00404-21. https://doi.org/10.1128/JVI.00404-21.

61. Johnson MC, Lydon TD, Suarez R, Salcedo B, LePique M, Graham M, Ricana C, Robinson C, Ritter DG. 2020. Optimized pseudotyping conditions for the SARS-CoV-2 Spike glycoprotein. J Virol 94:e01062-20. https://doi.org/10.1128/JVI.01062-20.

62. Havranek KE, Jimenez AR, Acciani MD, Fernanda M, Mendoza L, Mary J, Ballista R, Diaz DA, Brindley MA. 2020. SARS-CoV-2 Spike alterations alter sensitivity to neutralizing antibodies without increasing the envelope content of virions. J Virol 92:e01687-17. https://doi.org/10.1128/JVI.01687-17.

63. Fu X, Tao L, Zhang X. 2021. Comprehensive and systemic optimization for neutralization and validation of the TZM-bl assay for standardized assessments of SARSCoV-2 Spike envelope content of virions. J Virol 95:e01201-21. https://doi.org/10.1128/JVI.01201-21.

64. Ballista R, Diaz DA, Brindley MA. 2020. SARS-CoV-2 Spike alterations alter sensitivity to neutralizing antibodies without increasing the envelope content of virions. J Virol 92:e01687-17. https://doi.org/10.1128/JVI.01687-17.

65. Seaman MS, Chen B. 2015. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science 349:191–195. https://doi.org/10.1126/science.aaa9804.

66. White E, Wu F, Chertova E, Bess J, Roser JD, Lifson JD, Hirsch VM. 2017. Truncating the gp41 cytoplasmic tail of simian immunodeficiency virus decreases sensitivity to neutralizing antibodies without increasing the envelope content of virions. J Virol 92:e01687-17. https://doi.org/10.1128/JVI.01687-17.

67. Johnson MC, Lydon TD, Suarez R, Salcedo B, LePique M, Graham M, Ricana C, Robinson C, Ritter DG. 2020. Optimized pseudotyping conditions for the SARS-CoV-2 Spike glycoprotein. J Virol 94:e01062-20. https://doi.org/10.1128/JVI.01062-20.

68. Havranek KE, Jimenez AR, Acciani MD, Fernanda M, Mendoza L, Mary J, Ballista R, Diaz DA, Brindley MA. 2020. SARS-CoV-2 Spike alterations alter sensitivity to neutralizing antibodies without increasing the envelope content of virions. J Virol 92:e01687-17. https://doi.org/10.1128/JVI.01687-17.

69. Seaman MS, Chen B. 2015. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science 349:191–195. https://doi.org/10.1126/science.aaa9804.
66. Geraerts M, Michiels M, Baekelandt V, Debyser Z, Gijsbers R. 2005. Upscaling of lentiviral vector production by tangential flow filtration. J Gene Med 7:1299–1310. https://doi.org/10.1002/jgm.778.

67. Lorenzen-Redondo R, Nam HH, Roberts SC, Simons LM, Jennings LJ, Qi C, Achenbach CJ, Hauser AR, Isom MG, Hultquist JF, Ozor EA. 2020. A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways. EBioMedicine 62:103112. https://doi.org/10.1016/j.ebiom.2020.103112.

68. Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnoh KH, Leist SR, Schafer A, Nakajima N, Takahashi K, Lee RE, Masenck TM, Graham R, Edwards CE, Tse LV, Okuda K, Markmann AJ, Bartelt L, de Silva A, Margolis DM, Boucher RC, Randell SH, Suzuki T, Gralinski LE, Kawaoka Y, Baric RS. 2020. SARS-CoV-2 D614G variant exhibit efficient replication ex vivo and transmission in vivo. Science 370:1464–1468. https://doi.org/10.1126/science.abe8499.

69. Zhou B, Thi Huu Thao T, Hoffmann D, Taddeo A, Ebert N, Labroussaa F, Pohlmann A, King J, Steiner S, Kelly JN, Portmann J, Halwe NJ, Ulrich L, Trueb BS, Fan X, Hoffmann B, Wang L, Thomann L, Lin X, Stalder H, Pozzi B, de Brot S, Jiang N, Cui D, Hossain J, Wilson M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Lareau LF, Frankino PA, Shrivam H, Wyman SK, Ott M, Andino R, Chiu CY. 2021. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv https://doi.org/10.1101/2021.03.07.21252647.

70. Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-Gonzalez A, Glasner DR, Reyes KR, Giwara AS, Reddy NP, Sanchez C, Martin S, Federman S, Cheng J, Balcerek J, Taylor J, Streithorst JA, Miller S, Kumar GR, Sreekumar B, Chen P-Y, Schulze-Gahmen U, Taha TY, Hayashi J, Simoneau CR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Lareau LF, Frankino PA, Shrivam H, Wyman SK, Ott M, Andino R, Chiu CY. 2021. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv https://doi.org/10.1101/2021.03.07.21252647.

71. Whit MA. 2010. Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods 169:365–374. https://doi.org/10.1016/j.jviromet.2010.08.006.

72. Chen YW, Huang SX, De Carvalho ALRT, Ho SH, Islam MN, Volpi S, Notarangelo LD, Ciancianelli M, Casanova JL, Bhattacharya J, Liang AF, Sanchez C, Martin S, Federman S, Cheng J, Balcerek J, Taylor J, Streithorst JA, Miller S, Kumar GR, Sreekumar B, Chen P-Y, Schulze-Gahmen U, Taha TY, Hayashi J, Simoneau CR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Lareau LF, Frankino PA, Shrivam H, Wyman SK, Ott M, Andino R, Chiu CY. 2021. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv https://doi.org/10.1101/2021.03.07.21252647.

73. Cavazza-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, Cavallesco R, Gillet-Legrand B, Caccavelli L, Sgarra R, Maouche-Chrétien L, Bernaudin F, Girot R, Dorazio R, Mulder GJ, Polack A, Bank A, Soulier J, Larghero J, Kabbara N, Dalle B, Gourmel B, Socie G, Chrétien S, Cartier N, Aubourg P, Fischer A, Cornetta K, Galacteros F, Beuzard Y, Gluckman E, Bushman F, Hacein-Bey-Abina S, Leboulch P. 2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467:318–322. https://doi.org/10.1038/nature09328.

74. McAuley AJ, Kuiper MJ, Durr PA, Bruce MP, Barr J, Todd S, Au GG, Blasdell K, Tachedjian M, Lowther S, Marsh GA, Edwards S, Poole T, Layton R, Riddell S-JJ, Drew TW, Duce JD, Smith TRFF, Broderick KE, Vasan SS. 2020. Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. NPJ Vaccines 5:96. https://doi.org/10.1038/s41551-020-00246-8.

75. Yukselovski J, Wang X, Pascal KE, Tomkins-Tinch C, Nyalile TP, Wang Y, Baum A, Diehl WE, Dauphin A, Carbone C, Veinotte K, Egn S, Schaffner SF, Lemieux JE, Munro JB, Rauchte D, Sabaté PC, Kyrosatus CA, Dukkina NV, Shen K, Luban J. 2020. Structural and functional analysis of the D614G SARS-CoV-2 Spike protein variant. Cell 183:739–751. https://doi.org/10.1016/j.cell.2020.09.032.

76. Fernández A. 2020. Structural impact of mutation D614G in SARS-CoV-2 Spike protein: enhanced infectivity and therapeutic opportunity. ACS Med Chem Lett 11:1667–1670. https://doi.org/10.1021/acsmedchemlett.0c00410.

77. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, Cavallesco R, Gillet-Legrand B, Caccavelli L, Sgarra R, Maouche-Chrétien L, Bernaudin F, Girot R, Dorazio R, Mulder GJ, Polack A, Bank A, Soulier J, Larghero J, Kabbara N, Dalle B, Gourmel B, Socie G, Chrétien S, Cartier N, Aubourg P, Fischer A, Cornetta K, Galacteros F, Beuzard Y, Gluckman E, Bushman F, Hacein-Bey-Abina S, Leboulch P. 2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467:318–322. https://doi.org/10.1038/nature09328.